307 related articles for article (PubMed ID: 22192919)
1. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
[TBL] [Abstract][Full Text] [Related]
2. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC).
Saito J; Nakai Y; Saijo Y; Nukiwa T; Koinumaru S; Matsuura Y; Aso N; Yamane Y; Tsukamoto T; Sayama T; Nakabayashi T
Lung Cancer; 2001; 31(2-3):285-93. PubMed ID: 11165409
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced non-small cell lung cancer.
Minomo S; Asami K; Okishio K; Kawaguchi T; Fujita Y; Takata S; Tamura A; Saitou R; Atagi S
Anticancer Res; 2013 Mar; 33(3):1163-7. PubMed ID: 23482797
[TBL] [Abstract][Full Text] [Related]
6. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
[TBL] [Abstract][Full Text] [Related]
7. UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.
Ichinose Y; Seto T; Semba H; Itoh K; Inoue Y; Tanaka F; Araki J; Tamanoi M; Yamamoto H; Iwamoto N
Br J Cancer; 2005 Oct; 93(7):770-3. PubMed ID: 16175186
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
10. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group.
Ichinose Y; Yosimori K; Yoneda S; Kuba M; Kudoh S; Niitani H
Cancer; 2000 Jan; 88(2):318-23. PubMed ID: 10640963
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
[TBL] [Abstract][Full Text] [Related]
12. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Kusagaya H; Inui N; Karayama M; Nakamura Y; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Lung Cancer; 2012 Sep; 77(3):550-5. PubMed ID: 22705118
[TBL] [Abstract][Full Text] [Related]
13. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
[TBL] [Abstract][Full Text] [Related]
15. UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study.
Igishi T; Shigeoka Y; Yasuda K; Suyama H; Katayama S; Sugitani A; Matsumoto S; Yamamoto M; Ueda Y; Takeda K; Sumikawa T; Sako T; Kodani M; Hitsuda Y; Shimizu E
J Thorac Oncol; 2009 Mar; 4(3):376-82. PubMed ID: 19190514
[TBL] [Abstract][Full Text] [Related]
16. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
17. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Chen YM; Perng RP; Tsai CM; Whang-Peng J
Lung Cancer; 2006 Jun; 52(3):333-8. PubMed ID: 16554106
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
Laack E; Mende T; Benk J; Chemaissani A; Scholtze J; Lorenz C; Niestroy A; Dalhoff K; Müller T; Walter T; Dürk H; Edler L; Hossfeld DK
Eur J Cancer; 2001 Mar; 37(5):583-90. PubMed ID: 11290433
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
